Skip to main content
Illumina enters companion Dx development partnership with BMS

A partnership was reached by Illumina and Bristol-Myers Squibb to create and commercialize companion diagnostics for the pharmaceutical company's pipeline of oncology drugs. A diagnostic version of Illumina's TruSight Oncology 500 that will run on the NextSeq 550Dx is expected to be developed by the companies.

Full Story: